Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in 5-HT(1D) agonists.

M G Russell1

  • 1Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, CM20 2QR, UK. michael_russell@merck.com

Idrugs : the Investigational Drugs Journal
|September 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Royal Canadian Naval Nursing Service.

The Journal of the Canadian medical services·2010
Same author

N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands.

Journal of medicinal chemistry·2001
Same author

Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro.

European journal of pharmacology·2000
Same author

3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.

Journal of medicinal chemistry·1999
Same author

2,7-diazabicyclo[3.3.0]octanes as novel h5-HT receptor agonists.

Bioorganic & medicinal chemistry letters·1999
Same author

Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles.

Journal of medicinal chemistry·1999
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

New migraine treatments targeting 5-HT(1D/1B) receptors lack selectivity. Researchers developed selective 5-HT(1D) receptor agonists, L-775606 and PNU-109291, to reduce side effects and better understand migraine mechanisms.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Medicinal Chemistry

Background:

  • Sumatriptan and related 5-HT(1D/1B) receptor agonists are established migraine treatments.
  • Current agents lack selectivity between human 5-HT(1D) and 5-HT(1B) receptors, potentially causing side effects.
  • F-11356 is a recent, effective compound in this class but shares the selectivity issue.

Purpose of the Study:

  • To develop selective 5-HT(1D) receptor agonists.
  • To investigate compounds with potentially reduced vasoconstrictor liability.
  • To provide tools for understanding the role of 5-HT(1D) receptors in migraine pathophysiology.

Main Methods:

  • Drug discovery and development focused on receptor subtype selectivity.
  • Pharmacological profiling of novel compounds.

Related Experiment Videos

  • In vitro and potentially in vivo studies to assess efficacy and safety.

    • Main Results:

    • Discovery of selective 5-HT(1D) receptor agonists, specifically L-775606 and PNU-109291.
    • These compounds are anticipated to have reduced vasoconstrictor effects compared to non-selective agents.
    • L-775606 and PNU-109291 are identified as valuable research tools.

    Conclusions:

    • Selective 5-HT(1D) receptor agonists represent a promising therapeutic strategy for migraine.
    • These novel compounds may offer improved safety profiles by minimizing vasoconstrictor side effects.
    • L-775606 and PNU-109291 will aid in elucidating the specific contribution of 5-HT(1D) receptors to migraine treatment.